217 related articles for article (PubMed ID: 7519804)
1. [PSA in prostatic fluid].
Lehmann K; Simmler F; Schmucki O; Hauri D
Urologe A; 1994 May; 33(3):232-4. PubMed ID: 7519804
[TBL] [Abstract][Full Text] [Related]
2. Serum-to-urinary prostate-specific antigen ratio: a potential means of distinguishing benign prostatic hyperplasia from prostate cancer.
Irani J; Millet C; Levillain P; Doré B; Begon F; Aubert J
Eur Urol; 1996; 29(4):407-12. PubMed ID: 8791046
[TBL] [Abstract][Full Text] [Related]
3. [Correlation of IL-8 and IL-6 in prostatic fluid with serum prostate-specific antigen level in patients with benign prostatic hyperplasia complicated by prostatitis].
Ren X; Wu C; Yu Q; Zhu F; Liu P; Zhang H
Nan Fang Yi Ke Da Xue Xue Bao; 2016 Jan; 36(1):135-9. PubMed ID: 26806754
[TBL] [Abstract][Full Text] [Related]
4. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
Ho PJ; Baxter RC
Clin Endocrinol (Oxf); 1997 Mar; 46(3):333-42. PubMed ID: 9156044
[TBL] [Abstract][Full Text] [Related]
5. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
Ho PJ; Baxter RC
Clin Endocrinol (Oxf); 1997 Feb; 46(2):145-54. PubMed ID: 9135695
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of prostate-specific antigen and prostatic acid phosphatase in untreated prostatic carcinoma and benign prostatic hyperplasia.
Bogdanowicz JF; Bentvelsen FM; Oosterom R; Schroeder FH
Scand J Urol Nephrol Suppl; 1991; 138():97-103. PubMed ID: 1723815
[TBL] [Abstract][Full Text] [Related]
7. Significance of histological prostatitis in patients with urinary retention and underlying benign prostatic hyperplasia or adenocarcinoma of the prostate.
van Vuuren SP; Heyns CF; Zarrabi AD
BJU Int; 2012 Apr; 109(8):1194-7. PubMed ID: 21851551
[TBL] [Abstract][Full Text] [Related]
8. Reduction of PSA values by combination pharmacological therapy in patients with chronic prostatitis: implications for prostate cancer detection.
Magri V; Trinchieri A; Montanari E; Del Nero A; Mangiarotti B; Zirpoli P; de Eguileor M; Marras E; Ceriani I; Vral A; Perletti G
Arch Ital Urol Androl; 2007 Jun; 79(2):84-92. PubMed ID: 17695414
[TBL] [Abstract][Full Text] [Related]
9. Role of AgNOR count and its correlation with serum PSA levels in prostatic lesions.
Goel T; Garg S
Urol Int; 2009; 82(3):286-90. PubMed ID: 19440015
[TBL] [Abstract][Full Text] [Related]
10. Prostate health index and prostate cancer gene 3 score but not percent-free Prostate Specific Antigen have a predictive role in differentiating histological prostatitis from PCa and other nonneoplastic lesions (BPH and HG-PIN) at repeat biopsy.
De Luca S; Passera R; Fiori C; Bollito E; Cappia S; Mario Scarpa R; Sottile A; Franco Randone D; Porpiglia F
Urol Oncol; 2015 Oct; 33(10):424.e17-23. PubMed ID: 26162485
[TBL] [Abstract][Full Text] [Related]
11. Medically significant concentrations of prostate-specific antigen in serum assessed.
Bernstein LH; Rudolph RA; Pinto MM; Viner N; Zuckerman H
Clin Chem; 1990 Mar; 36(3):515-8. PubMed ID: 1690092
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of histological prostatitis in men with benign prostatic hyperplasia or adenocarcinoma of the prostate presenting without urinary retention.
Edlin RS; Heyns CF; Van Vuuren SP; Zarrabi AD
S Afr J Surg; 2012 Nov; 50(4):127-30. PubMed ID: 23217554
[TBL] [Abstract][Full Text] [Related]
13. Ratio of free-to-total prostate specific antigen in serum cannot distinguish patients with prostate cancer from those with chronic inflammation of the prostate.
Jung K; Meyer A; Lein M; Rudolph B; Schnorr D; Loening SA
J Urol; 1998 May; 159(5):1595-8. PubMed ID: 9554361
[TBL] [Abstract][Full Text] [Related]
14. Prostate specific antigen in the expressed prostatic fluid of men with benign prostatic hyperplasia and prostate carcinoma.
Kim ED; Smith ND; Grayhack JT
J Urol; 1995 Nov; 154(5):1802-5. PubMed ID: 7563351
[TBL] [Abstract][Full Text] [Related]
15. [Established oneself the detection of serum prostate specific antigen and application in clinical practice].
Feng T; Dou CQ; Xia TL
Zhonghua Wai Ke Za Zhi; 1994 Nov; 32(11):685-7. PubMed ID: 7539736
[TBL] [Abstract][Full Text] [Related]
16. Presence of PSA auto-antibodies in men with prostate abnormalities (prostate cancer/benign prostatic hyperplasia/prostatitis).
Lokant MT; Naz RK
Andrologia; 2015 Apr; 47(3):328-32. PubMed ID: 24620795
[TBL] [Abstract][Full Text] [Related]
17. The role of prostate-specific antigen in the evaluation of benign prostatic hyperplasia.
Tchetgen MB; Oesterling JE
Urol Clin North Am; 1995 May; 22(2):333-44. PubMed ID: 7539179
[TBL] [Abstract][Full Text] [Related]
18. [Prostate-specific antigen in patients with benign prostatic hyperplasia].
Goncalves F; Kausitz J; Bárdos A; Miklosi M
Rozhl Chir; 1994 Sep; 73(6):291-3. PubMed ID: 7536350
[TBL] [Abstract][Full Text] [Related]
19. Prostate-specific antigen (PSA) and cancer-associated serum antigen (CASA) in distinguishing benign and malignant prostate disease.
Devine PL; Walsh MD; McGuckin MA; Quin RJ; Hohn BG; Clague A; Samaratunga H
Int J Biol Markers; 1995; 10(4):221-5. PubMed ID: 8750649
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of prostate-specific antigen in untreated prostatic carcinoma.
Oosterom R; Bogdanowicz J; Schröder FH
Eur Urol; 1989; 16(4):253-7. PubMed ID: 2475344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
